Antifungal resistance in dermatophytes - review of the epidemiology, diagnostic challenges and treatment strategies for managing infections.

INTRODUCTION

There is an increasing number of reports of infections. This species is usually poorly responsive to terbinafine.

AREAS COVERED

A literature search was conducted in May 2024. infections detected outside the Indian subcontinent are generally associated with international travel. Reports of local spread are mounting.As a newly identified dermatophyte species closely related to the complex with limited genetic and phenotypic differences, there is an unmet need to develop molecular diagnosis for . Terbinafine has become less effective as a first-line agent attributed to mutations in the squalene epoxidase gene (Leu393Phe, Phe397Leu). Alternative therapies include itraconazole for a longer time-period or a higher dose (200 mg/day or higher). Generally, fluconazole and griseofulvin are not effective. In some cases, especially when the area of involvement is relatively small, topical non-allylamine antifungals may be an option either as monotherapy or in combination with oral therapy. In instances when the patient relapses after apparent clinical cure then itraconazole may be considered. Good antifungal stewardship should be considered at all times.

EXPERT OPINION

When both terbinafine and itraconazole are ineffective, options include off-label triazoles (voriconazole and posaconazole). We present four patients responding to these newer triazoles.